 "lupin")
Drug maker Lupin on Friday said it has received approval from the US health regulator to market Drospirenone tablets, used to prevent pregnancy, in the American market.
The company has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Drospirenone Tablets in 4 mg strength, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Exeltis USA Inc's Slynd tablets, it added.
As per IQVIA MAT September 2022 data, Drospirenone tablets had estimated annual sales of USD 141 million in the US market.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
